Cation exchange chromatography on a monodisperse 3 µm particle enables extensive analytical similarity assessment of biosimilars

J Pharm Biomed Anal. 2023 Sep 20:234:115534. doi: 10.1016/j.jpba.2023.115534. Epub 2023 Jun 16.

Abstract

Biosimilarity assessment requires extensive characterization and comparability exercises to investigate product quality attributes of an originator product and its potential biosimilar(s) and to highlight any differences between them. Performing a thorough comparison allows a shortened approval path, which also eliminates lengthy and expensive clinical trials, ensuring comparable product quality and efficacy but at lower drug prices. The wide variety of analytical methods available for biosimilar assessment ranges from biological to analytical assays, each providing orthogonal information to fully characterize biosimilar candidates. Intact native mass spectrometry (MS) has been shown to be an excellent tool for detection and monitoring of important quality attributes such as N-glycosylation, deamidation, sequence truncation and higher order structures. When combined with efficient upfront separation methods, simplification of the proteoform heterogeneity and associated complexity prior to MS analysis can be achieved. Native mass spectrometry can provide robust and accurate results within short analysis times and requires minimal sample preparation. In this study we report the use of a monodisperse strong cation exchange chromatography phase hyphenated with Orbitrap mass spectrometry (SCX-MS) to compare the best-selling biopharmaceutical product Humira® with 7 commercially approved biosimilar products. SCX-MS analysis allowed for the identification of previously described as well as so far unreported proteoforms and their relative quantitation across all samples, revealing differences in N-glycosylation and lysine truncation, as well as unique features for some products such as sialylation and N-terminal clipping. SCX-MS analysis, powered by a highly efficient separation column, enabled deep and efficient analytical comparison of biosimilar products.

Keywords: Adalimumab; Biosimilars; Cation exchange; Charge variant analysis; Monoclonal antibody; Native mass spectrometry.

Publication types

  • Review

MeSH terms

  • Adalimumab / chemistry
  • Biosimilar Pharmaceuticals* / chemistry
  • Chromatography
  • Glycosylation
  • Mass Spectrometry / methods

Substances

  • Biosimilar Pharmaceuticals
  • Adalimumab